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Abstract
Background: To date, no studies have sought to determine the frequency of malignancy in patients
presenting with a putative biliary stricture and normal liver function tests (LFTs). The primary aim of this
retrospective cohort study was to determine the likelihood of malignancy in patients presenting with a
biliary stricture and normal LFTs, a normal bilirubin level either alone or in combination with normal
levels of liver enzymes [alkaline phosphatase (ALP) and alanine transaminase (ALT)]. A secondary aim
was to determine any clinical/biochemical/sonographic features that may be associated with malig-
nancy.
Methods: Patients presenting over a 10-year period were included. Fifteen variables were analysed to
determine their association with malignant disease.
Results: Eight hundred and thirty patients with putative biliary strictures were included. Primary
hepatopancreaticobiliary (HPB) cancers presented with a normal bilirubin and normal liver enzymes
(ALP and ALT) in 6% of cases. Patients with a putative biliary stricture and a normal bilirubin level
whose final diagnoses were pancreatic cancer, ampullary cancer, distal cholangiocarcinoma and hilar
cholangiocarcinoma represented 21%, 13%, 7% and 9% of individuals diagnosed with these patholo-
gies, respectively. Hypoalbuminaemia and isolated intrahepatic duct dilatation on ultrasound were
significantly associated with malignancy in patients with normal bilirubin and completely normal LFTs.
Conclusions: This study has shown that patients with a putative biliary stricture and completely
normal LFTs are unlikely to have a primary HPB malignancy. Those presenting with a normal bilirubin
level, but deranged liver enzymes (ALP and/or ALT), are more likely to have malignant disease, and this
should necessitate a higher degree of clinical suspicion.
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Introduction
Differentiating between benign and malignant biliary strictures
can be challenging despite the utilization of advanced imaging
modalities and endoscopic techniques. Pre-operative histologi-
cal confirmation of malignancy is not usually possible prior to
surgical exploration and resection. Biopsies, brushings and
fine-needle aspiration (FNA) samples obtained during endo-
scopic retrograde cholangiopancreatography (ERCP) may yield
a definitive tissue diagnosis; however, the combined sensitivity
of these techniques is in the region of 60%.1,2 The reported
sensitivity of endoscopic ultrasound (EUS) and FNA for the
diagnosis of a malignant stricture varies widely from 43% to
86%.3–5 The combination of ERCP and EUS may improve the
rate of pre-operative histological confirmation of malignancy;
however, for a significant proportion of patients the decision
to operate is based on a review of clinical, biochemical and
radiological features.
Appearances on cross-sectional imaging and levels of tumour
markers, particularly CA19-9 (carbohydrate antigen 19-9), are
routinely used in the assessment of suspicious biliary strictures.
Also, elevated liver function tests (LFTs) at presentation,
including bilirubin, alkaline phosphatase (ALP) and alanine
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transaminase (ALT) have been associated with an increased
likelihood of malignancy.6–10 Bilirubin levels, in particular,
have been consistently identified as a strong predictor of malig-
nant disease, indeed the higher the bilirubin level at presenta-
tion the greater the likelihood of malignancy.11 To date, no
studies have sought to determine the likelihood of malignancy
in patients presenting with normal LFTs. The aim of this study
was to investigate the probability of malignant disease in
patients presenting with a putative biliary stricture and normal
LFTs (either a normal bilirubin level alone or normal bilirubin
and normal liver enzymes). A secondary aim was to determine
any clinical, biochemical or sonographic features in patients
with normal LFTs that may be discernable at presentation and
associated with an increased likelihood of malignancy.
Patients and methods
Patients with putative biliary strictures who were discussed at
the Leicester Hepatopancreaticobiliary (HPB) Multidisciplinary
Team (MDT) meeting during the last 10 years were included
in the study. Data relating to demographics, symptoms and
blood test results at presentation, radiological/intervention
findings and final diagnoses were extracted from our prospec-
tive database. Patients’ case notes were also reviewed for
further information. Patients with only a normal bilirubin at
presentation and those with three normal parameters (ALP,
ALT and bilirubin) were analysed in groups according to
whether they had benign or malignant disease. Final diagnoses
were based on histology (using either resected specimens, tis-
sue obtained at surgical exploration, brushings from ERCP
or biopsy material acquired radiologically/laparoscopically),
interval imaging (at least two cross-sectional scans performed
≥6 months apart, all reviewed at the HPB MDT meeting
and showing no disease progression in the case of benign
disease) and findings during interventions such as ERCP and
surgery.
Statistical methods
Fifteen variables were used to compare groups; patients pre-
senting with a normal bilirubin and benign/malignant disease
and patients presenting with three normal LFTs and benign/
malignant disease. The 15 variables utilized were demographic
factors (age, gender), symptoms at presentation (pain, weight
loss and anorexia), blood results at presentation (haemoglobin,
white cell count, neutrophil to lymphocyte ratio, platelet
count, CA 19.9 and albumin) and ultrasound (USS) findings
common bile duct (CBD) size, isolated CBD dilatation, iso-
lated intrahepatic duct (IHD) dilatation and dilatation of both
the CBD and IHD; CBD dilatation was defined as >7 mm
diameter, IHD dilatation was defined as either ≥2 mm diame-
ter or >40% of the diameter of an adjacent portal vein
branch). Depending on the nature of the variable, its associa-
tion with benign/malignant disease, was determined using the
unpaired t-test (with normality confirmed using the Shapiro–
Wilk test) and chi-squared/Fisher’s tests. Statistical significance
was defined as P < 0.05. Those variables that were significantly
associated with either benign or malignant disease were analy-
sed in further detail. Sensitivity, specificity, positive predictive
values (PPV) and negative predictive values (NPV) were calcu-
lated, along with the area under the curve (AUC) from recei-
ver-operating characteristic (ROC) analysis. For calculation of
sensitivity, specificity, PPV and NPV continuous data were
dichotomized on the basis of the normal range for the variable.
Statistical analyses were performed using Statistical Package for
the Social Sciences 20.0© (SPSS, Chicago, IL, USA).
Results
A total of 830 patients with putative biliary strictures were dis-
cussed at the specialist HPB MDT meeting. Of these discussed
biliary strictures, 492 were benign, 269 were malignant and the
remainder were uncertain in nature (owing to patients either
declining or being too frail for further investigation). (Fig. 1)
Of the 269 patients with malignant disease, the diagnosis was
based on histology in 127 (47%); this was obtained endoscopi-
cally, percutaneously and at laparoscopy and laparotomy in 11,
25, 47 and 44 patients, respectively. A diagnosis of malignancy
in the remaining 142 patients was based on cross-sectioning
imaging showing clear evidence of metastatic disease. Histolog-
ical confirmation was not sought in this group as they were
managed palliatively.
Likelihood of malignancy in patients with normal
bilirubin
A normal bilirubin level at presentation was observed in 267
patients with a benign stricture (54%) and 59 patients with a
malignant stricture (22%). Patients with a putative biliary
stricture and a normal bilirubin level whose final diagnoses
were pancreatic cancer, ampullary cancer, distal cholangiocarci-
noma and hilar cholangiocarcinoma represented 21%, 13%,
7% and 9% of individuals diagnosed with these pathologies,
respectively. Table 1 summarizes demographic data and the
final diagnoses for this group of patients.
Likelihood of malignancy in patients with normal
bilirubin and normal liver enzymes (ALP and/or ALT)
Bilirubin, ALP and ALT levels were all within normal limits in
126 patients with benign disease (26%) and 16 patients with
malignant disease (6%). Table 2 summarizes demographic data
and final diagnoses for this group.
Predictors of malignancy in patients with normal
bilirubin
Clinical factors significantly associated with malignant disease
in the presence of a normal bilirubin level were weight loss
(P = 0.002), anorexia (P = 0.006), hypoalbuminaemia
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(P = 0.033) and isolated dilatation of the intrahepatic ducts
on USS (P < 0.001). Although these variables exhibited high
specificity (>85%) and NPV (>82%) sensitivity and PPV
were low (<31% and <47%, respectively). Consequently,
ROC analysis revealed poor AUC values for these variables
(≤0.6) (Table 3).
Predictors of benign disease in patients with normal
bilirubin
Clinical factors significantly associated with benign disease in
the presence of a normal bilirubin were isolated dilatation of
the CBD (P < 0.001), dilatation of both the intrahepatic ducts
and CBD (P = 0.023) and the degree of CBD dilatation
(P = 0.001). The PPV for these variables were notably high
(>86%); however, an inverse correlation between sensitivity
and specificity was present. AUC values compared favourably
with those obtained for variables associated with malignancy
and a normal bilirubin, but the absolute numbers were poor
(≤ 0.69) (Table 4).
Table 2 Characteristics of patients with biliary strictures and three
normal LFTs
Characteristic Malignant (n = 16) Benign (n = 126)
Male gender,
n (%)
5 (31) 44 (35)
Median age,
years (range)
73 (32–87) 67 (25–88)
Stricture
aetiology,
n (%)
Cholangiocarcinoma,
9 (56)
Stones/sludge, 32 (25)
Recurrent
cholangiocarcinoma,
3 (19)
Physiological, 22 (17)
Other, 4 (25)a Benign stricture, 16 (13)
Post cholecystectomy,
12 (10)
Chronic pancreatitis,
10 (8)
Other, 34 (27)a
LFTs, liver function tests.
a
Other causes which individually represent < 5% of the total.
Patients with a biliary stricture (n = 830)
Benign 
(n = 492)
Malignant
(n = 269)
Uncertain in nature 
(n = 69)
High bilirubin 
(n = 225)
Normal bilirubin 
(n = 267)
Normal bilirubin 
(n = 59)
High bilirubin 
(n = 210) 
High ALP +/–
ALT (n = 43)
3 normal LFTs
(n = 16)
High ALP +/–
ALT (n = 141)
3 normal LFTs 
(n = 126)
Figure 1 A breakdown of the patients included in the study by disease status and liver function tests (LFTs). ALP, alkaline phosphatase
Table 1 Characteristics of patients with biliary strictures and a
normal bilirubin
Characteristic Malignant (n = 59) Benign (n = 267)
Male gender,
n (%)
18 (31) 102 (38)
Median age,
years (range)
71 (25–95) 68 (18–94)
Stricture
aetiology,
n (%)
Cholangiocarcinoma,
28 (47)
Stones/Sludge, 82 (31)
Pancreatic cancer,
5 (8)
Benign stricture, 34 (13)
Other, 26 (44)a Physiological, 33 (12)
Chronic pancreatitis,
26 (10)
Post cholecystectomy,
16 (6)
Other, 85 (32)a
a
Other causes which individually represent < 5% of the total.
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Predictors of malignancy in patients with a normal
bilirubin and normal liver enzymes (ALP and/or ALT)
A leukocytosis, thrombocytosis, hypoalbuminaemia and iso-
lated dilatation of the IHD on USS were all significantly
associated with malignant disease in the presence of com-
pletely normal LFTS. Further analysis revealed comparable
results with those obtained for variables significantly associ-
ated with malignant disease in patients with normal biliru-
bin. High specificities (>88%) and NPV (>89%) were
evident, with low sensitivities (<44%), PPV (≤40%) and
AUC (≤0.66) (Table 3).
Discussion
This large series of patients who were investigated for putative
biliary strictures demonstrates that primary malignant HPB
pathology is extremely uncommon in the presence of com-
pletely normal LFTs. Patients with completely normal LFTs
who received final diagnoses of pancreatic cancer, ampullary
cancer, distal and hilar cholangiocarcinomas represented 6% of
individuals with these pathologies. Patients with a normal bili-
rubin, but deranged liver enzymes (ALP and/or ALT), who
were investigated for a possible biliary stricture were far more
likely to have a primary HPB malignancy. For example, 21%
of patients who were investigated for putative stricture and
diagnosed with pancreatic cancer had a normal bilirubin at ini-
tial presentation, with elevated ALP and/or ALT levels. It may
be that patients presenting with a normal bilirubin are at an
earlier stage in the natural course of these malignancies. This is
supported by the fact that a greater proportion of patients with
hilar cholangiocarcinomas had resectable disease when they
presented with a normal rather than a high bilirubin (14%
versus 4%) although the numbers involved were small and,
therefore, not statistically significant. No differences were
observed in the rates of resection between individuals present-
ing with a putative stricture and a normal or raised bilirubin
level in whom the final diagnoses were pancreatic cancer,
ampullary cancer or distal cholangiocarcinoma. However, these
conditions represented a smaller proportion of the series of
malignant biliary strictures compared with hilar cholangiocar-
cinomas.
Previous studies which have sought to determine clinical
factors associated with malignancy in patients with a biliary
stricture have consistently identified a high bilirubin level,
along with derangements in other LFTs, as the best predic-
tors of malignant disease. In addition, high levels of CA19-9,
age, weight loss, anorexia and IHD dilation on USS have
been associated with malignancy (Table 5).6–10 To date, these
studies have involved relatively small numbers of patients
and have not addressed patients presenting with a normal
bilirubin or LFTs. This study has shown that a number of
factors are significantly associated with malignant disease in
the presence of a normal bilirubin and normal LFTs
(Table 3). Although highly specific (> 85%), the sensitivity
Table 3 Analysis of factors significantly associated with malignant disease in patients with a normal bilirubin and patients with three
normal LFTs
Factor Sensitivity (%) Specificity (%) PPV (%) NPV (%) AUC 95% CI
Normal bilirubin
Weight loss 30.5 85.9 31.6 85.3 0.58 0.50–0.67
Anorexia 10.2 97.5 46.2 83.5 0.54 0.45–0.62
Low albumin (<35 g/l) 11.3 94.4 31.6 82.2 0.53 0.44–0.62
Isolated dilatation IHD 28.6 91.5 46.2 83.4 0.60 0.52–0.68
Three normal LFTs
High white cell count (>11 9 109/l) 43.8 88.3 35.0 91.6 0.66 0.50–0.82
High platelet count (>400 9 109/l) 25.0 90.1 26.7 89.3 0.58 0.41–0.74
Low albumin (<35 g/l) 12.5 97.6 40.0 89.8 0.55 0.39–0.71
Isolated IHD dilatation 33.3 93.3 37.5 92.1 0.62 0.46–0.78
LFTs, liver function tests; IHD, intrahepatic duct; PPV, positive predictive values; NPV, negative predictive values; AUC, area under the curve.
Table 4 Analysis of factors significantly associated with benign disease in patients with a normal bilirubin
Factor Sensitivity (%) Specificity (%) PPV (%) NPV (%) AUC 95% CI
Isolated dilatation CBD 33.9 92.9 94.9 26.4 0.65 0.58–0.72
Dilatation CBD and IHD 41.2 74.4 86.1 24.8 0.60 0.52–0.68
Degree of CBD dilatation (>7 mm) 79.3 58.8 91.8 32.8 0.69 0.59–0.79
IHD, intrahepatic duct; PPV, positive predictive values; NPV, negative predictive values; AUC, area under the curve, CI, confidence interval.
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of these variables is low (< 44%) yielding low AUC values
(≤ 0.66). Hypoalbuminaemia and isolated IHD dilatation on
USS were significantly associated with malignancy in both the
presence of a normal bilirubin and normal LFTs. Hypoalbu-
minaemia secondary to nutritional deficiency and cachexia
typify terminal HPB cancers. In the earlier stages, it has been
postulated that reductions in serum albumin concentrations
arise from Systemic Inflammatory Response Syndrome (SIRS)
initiated by the presence of malignant cells. Hypoalbumina-
emia as a consequence of SIRS may result from reduced syn-
thesis, enhanced degradation and altered distribution.12–14
Isolated IHD dilatation, along with hyperbilirubinaemia, has
been significantly associated with malignancy in previous
studies.6,7 This series shows that IHD dilatation remains a
predictor of malignancy even in the absence of jaundice.
Isolated IHD dilatation implies obstruction at the hilum or
beyond which would arise less commonly from benign
aetiologies. In addition, the degree of obstruction arising from
benign conditions is likely to be less pronounced. For
example, up to one-third of bile duct calculi are found in
non-dilated ducts.15
Despite previous studies having shown significant associa-
tions between elevated levels of CA19-9 and the presence of
malignant biliary strictures,8 this series failed to demonstrate
such an association. A range of benign HPB conditions have
been associated with abnormal elevations of CA19-9, such as
Mirizzi syndrome and autoimmune pancreatitis. Also, previous
data have shown a correlation between hyperbilirubinaemia
and elevated levels of CA19-916 which may explain why this
series, focusing on patients with normal LFTs, failed to estab-
lish an association between CA19-9 level and the presence of
malignancy. The CA19-9 level is associated with disease
progression17 and a low CA19-9 level, with a normal bilirubin
suggests early stage disease.
A number of findings on USS were significantly associated
with the presence of benign disease; isolated CBD dilatation,
dilatation of the CBD and IHD and the degree of CBD dilata-
tion. An inverse correlation between sensitivity and specificity
for these variables resulted in ROC analysis yielding poor AUC
values (≤0.69). Isolated dilatation of the CBD exhibited a nota-
bly high specificity for benign disease (92.9%). In accordance
with this finding, four recent studies have demonstrated a very
low yield of malignant pathology from performing EUS in
individuals with CBD dilatation and normal LFTs.18–21 Bruno
et al.19 report one case of malignancy, pancreatic cancer,
detected by EUS.
Although a number of factors in this study were associated
with the presence of benign/malignant biliary strictures, the
sensitivity of these variables was low yielding low AUC values.
Additional variables that could be considered as potential dis-
criminators between benign and malignant disease in future
studies include other factors present in the history, for example
symptom duration. It would also be interesting to consider the
potential correlations between specific LFTs and the presence
of malignancy, ALP and ALT but also aspartate aminotransfer-
ase (AST) and Gamma-Glutamyl Transpeptidase. Although
outside the scope of this study, which focused on variables
available at presentation, further discriminators between benign
and malignant disease may include specific appearances on
cross-sectional imaging.
Conclusion
This study has shown that patients with a putative stricture
and completely normal LFTs are unlikely to have primary HPB
malignant pathology. Those presenting with a normal bilirubin
but deranged ALP and/or ALT are more likely to have malig-
nant disease necessitating a higher degree of clinical suspicion.
This is particularly important as patients with normal bilirubin
may have earlier stage disease that could be amenable to resec-
tion. Hypoalbuminaemia and isolated IHD dilatation on USS
are significantly associated with the presence of malignancy in
patients with normal bilirubin and normal LFTs, exhibiting a
high degree of specificity. Isolated dilatation of the CBD is
significantly associated with benign disease in patients with
normal bilirubin and is a highly specific finding.
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